ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1765

Glycol Chitosan-Based Tacrolimus-Loaded Nanomicelle Therapy Ameliorates Lupus Nephritis

Session Information

Category: Glomerular Diseases

  • 1202 Glomerular Diseases: Immunology and Inflammation

Authors

  • Kim, Chang Seong, Chonnam National University, Gwangju, Jeollanam-do, Korea (the Republic of)
  • Oh, Tae ryom, Chonnam National University, Gwangju, Jeollanam-do, Korea (the Republic of)
  • Choi, Hong sang, Chonnam National University, Gwangju, Jeollanam-do, Korea (the Republic of)
  • Bae, Eun Hui, Chonnam National University, Gwangju, Jeollanam-do, Korea (the Republic of)
  • Ma, Seong Kwon, Chonnam National University, Gwangju, Jeollanam-do, Korea (the Republic of)
  • Kim, Soo Wan, Chonnam National University, Gwangju, Jeollanam-do, Korea (the Republic of)
Background

Hydrophobically modified glycol chitosan (HGC) nanomicelles loaded with tacrolimus (HGC-TAC) enhance the renal delivery of tacrolimus. Here, we determined whether the administration of HGC-TAC nanomicelles decreases kidney injury in a model of lupus nephritis.

Methods

Lupus-prone female MRL/lpr mice were randomly divided into 2 groups and given either intravenous vehicle or HGC-TAC (0.5 mg/kg tacrolimus) weekly for 8 weeks. Age-matched MRL/MpJ mice without Faslpr mutation were treated with a vehicle and used as healthy controls.

Results

Weekly treatment with intravenous HGC-TAC remarkably reduced genetically attributable lupus activity, blood urea nitrogen, and proteinuria in lupus nephritis-positive mice. In addition, HGC-TAC treatment mitigated renal dysfunction and histological injury, including glomerular proliferative lesions and tubulointerstitial infiltration. Furthermore, HGC-TAC treatment reduced renal inflammation and inflammatory gene expression, as well as ameliorated the increased glomerular fibrosis. Moreover, the administration of HGC-TAC appeared to regulate renal injury via the TGF-β1/p38MAPK/NF-κB signaling pathway.

Conclusion

Our study clearly indicates that weekly treatment with HGC-TAC nanomicelles reduces kidney injury resulting from lupus nephritis by preventing inflammation and fibrosis. This advantage of HGC-TAC nanocarriers may improve drug adherence and treatment efficacy in lupus nephritis patients.

Funding

  • Government Support - Non-U.S.